[
  {
    "ts": null,
    "headline": "Here's Why You Should Retain CONMED Stock in Your Portfolio for Now",
    "summary": "CNMD's growth rests on AirSeal, Buffalo Filter and BioBrace as supply chains normalize, even as tariffs and a GI exit pressure EPS.",
    "url": "https://finnhub.io/api/news?id=28141f25a20c091e9a3153bb10fb79dd03596d1ac66eae0d291041ec537d54e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770746400,
      "headline": "Here's Why You Should Retain CONMED Stock in Your Portfolio for Now",
      "id": 139035023,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "CNMD's growth rests on AirSeal, Buffalo Filter and BioBrace as supply chains normalize, even as tariffs and a GI exit pressure EPS.",
      "url": "https://finnhub.io/api/news?id=28141f25a20c091e9a3153bb10fb79dd03596d1ac66eae0d291041ec537d54e3"
    }
  },
  {
    "ts": null,
    "headline": "ECL Stock Falls in Pre-Market Despite Q4 Earnings Beat, Margins Expand",
    "summary": "Ecolab posts strong Q4 earnings with margin expansion and solid segment growth, but cautious sentiment persists despite gains in water, pest and life sciences.",
    "url": "https://finnhub.io/api/news?id=be0354c664c158516e5e1132219a0cc1cf0f7b80ae18c2dda3bc33b148d8e372",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770744600,
      "headline": "ECL Stock Falls in Pre-Market Despite Q4 Earnings Beat, Margins Expand",
      "id": 139035004,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Ecolab posts strong Q4 earnings with margin expansion and solid segment growth, but cautious sentiment persists despite gains in water, pest and life sciences.",
      "url": "https://finnhub.io/api/news?id=be0354c664c158516e5e1132219a0cc1cf0f7b80ae18c2dda3bc33b148d8e372"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Becton, Dickinson: “I Kind of Really Like the New Company”",
    "summary": "Becton, Dickinson and Company (NYSE:BDX) is one of the stocks in focus on Jim Cramer’s game plan. Cramer showed bullish sentiment toward the company, as he said: Now, there’s been some incredible moves happening in the medical devices distribution space this quarter. The once unsinkable Boston Scientific got clobbered this week because the competition got […]",
    "url": "https://finnhub.io/api/news?id=ff67fcd3dda7f6ebad406309b8486173b0e656688f97b2337ba5c01d747d8334",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770739118,
      "headline": "Jim Cramer on Becton, Dickinson: “I Kind of Really Like the New Company”",
      "id": 139032013,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Becton, Dickinson and Company (NYSE:BDX) is one of the stocks in focus on Jim Cramer’s game plan. Cramer showed bullish sentiment toward the company, as he said: Now, there’s been some incredible moves happening in the medical devices distribution space this quarter. The once unsinkable Boston Scientific got clobbered this week because the competition got […]",
      "url": "https://finnhub.io/api/news?id=ff67fcd3dda7f6ebad406309b8486173b0e656688f97b2337ba5c01d747d8334"
    }
  },
  {
    "ts": null,
    "headline": "Wells Fargo Maintains Overweight on Cardinal Health, Raises Price Target to $256",
    "summary": "Wells Fargo  analyst Stephen Baxter   maintains Cardinal Health (NYSE:CAH) with a Overweight and raises the price target from $237 to $256.",
    "url": "https://finnhub.io/api/news?id=77ad163f8c4a931ed520e29e033c582cbf1a23f89a9f33c968da76d77c9b4477",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770717651,
      "headline": "Wells Fargo Maintains Overweight on Cardinal Health, Raises Price Target to $256",
      "id": 139031355,
      "image": "",
      "related": "CAH",
      "source": "Benzinga",
      "summary": "Wells Fargo  analyst Stephen Baxter   maintains Cardinal Health (NYSE:CAH) with a Overweight and raises the price target from $237 to $256.",
      "url": "https://finnhub.io/api/news?id=77ad163f8c4a931ed520e29e033c582cbf1a23f89a9f33c968da76d77c9b4477"
    }
  }
]